168 related articles for article (PubMed ID: 34410453)
1. Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice.
Newe M; Kant TA; Hoffmann M; Rausch JSE; Winter L; Künzel K; Klapproth E; Günther C; Künzel SR
Naunyn Schmiedebergs Arch Pharmacol; 2021 Nov; 394(11):2233-2244. PubMed ID: 34410453
[TBL] [Abstract][Full Text] [Related]
2. Genetic Deletion of Polo-Like Kinase 2 Induces a Pro-Fibrotic Pulmonary Phenotype.
Kant TA; Newe M; Winter L; Hoffmann M; Kämmerer S; Klapproth E; Künzel K; Kühnel MP; Neubert L; El-Armouche A; Künzel SR
Cells; 2021 Mar; 10(3):. PubMed ID: 33799608
[TBL] [Abstract][Full Text] [Related]
3. Repurposing mesalazine against cardiac fibrosis in vitro.
Hoffmann M; Kant TA; Emig R; Rausch JSE; Newe M; Schubert M; Künzel K; Winter L; Klapproth E; Peyronnet R; Ravens U; El-Armouche A; Künzel SR
Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):533-543. PubMed ID: 33064167
[TBL] [Abstract][Full Text] [Related]
4. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin in systemic sclerosis and its role in dermal fibrosis.
Wu M; Schneider DJ; Mayes MD; Assassi S; Arnett FC; Tan FK; Blackburn MR; Agarwal SK
J Invest Dermatol; 2012 Jun; 132(6):1605-14. PubMed ID: 22402440
[TBL] [Abstract][Full Text] [Related]
6. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP
Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.
Zhang Y; Dees C; Beyer C; Lin NY; Distler A; Zerr P; Palumbo K; Susok L; Kreuter A; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2015 May; 74(5):936-43. PubMed ID: 24431397
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis.
Lorenzen JM; Schauerte C; Hübner A; Kölling M; Martino F; Scherf K; Batkai S; Zimmer K; Foinquinos A; Kaucsar T; Fiedler J; Kumarswamy R; Bang C; Hartmann D; Gupta SK; Kielstein J; Jungmann A; Katus HA; Weidemann F; Müller OJ; Haller H; Thum T
Eur Heart J; 2015 Aug; 36(32):2184-96. PubMed ID: 25898844
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin expression is required for myofibroblast differentiation.
Lenga Y; Koh A; Perera AS; McCulloch CA; Sodek J; Zohar R
Circ Res; 2008 Feb; 102(3):319-27. PubMed ID: 18079410
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.
Beyer C; Reich N; Schindler SC; Akhmetshina A; Dees C; Tomcik M; Hirth-Dietrich C; von Degenfeld G; Sandner P; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 Jun; 71(6):1019-26. PubMed ID: 22294631
[TBL] [Abstract][Full Text] [Related]
12. Function-Blocking RHAMM Peptides Attenuate Fibrosis and Promote Antifibrotic Adipokines in a Bleomycin-Induced Murine Model of Systemic Sclerosis.
Wu KY; Kim S; Liu VM; Sabino A; Minkhorst K; Yazdani A; Turley EA
J Invest Dermatol; 2021 Jun; 141(6):1482-1492.e4. PubMed ID: 33242499
[TBL] [Abstract][Full Text] [Related]
13. Mesalazine, an osteopontin inhibitor: The potential prophylactic and remedial roles in induced liver fibrosis in rats.
Ramadan A; Afifi N; Yassin NZ; Abdel-Rahman RF; Abd El-Rahman SS; Fayed HM
Chem Biol Interact; 2018 Jun; 289():109-118. PubMed ID: 29738702
[TBL] [Abstract][Full Text] [Related]
14. TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis.
Laurent P; Allard B; Manicki P; Jolivel V; Levionnois E; Jeljeli M; Henrot P; Izotte J; Leleu D; Groppi A; Seneschal J; Constans J; Chizzolini C; Richez C; Duffau P; Lazaro E; Forcade E; Schaeverbeke T; Pradeu T; Batteux F; Blanco P; Contin-Bordes C; Truchetet ME
Ann Rheum Dis; 2021 Dec; 80(12):1594-1603. PubMed ID: 34285051
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.
Tomcik M; Zerr P; Pitkowski J; Palumbo-Zerr K; Avouac J; Distler O; Becvar R; Senolt L; Schett G; Distler JH
Ann Rheum Dis; 2014 Jun; 73(6):1215-22. PubMed ID: 23661493
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
17. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis.
Huber LC; Distler JH; Moritz F; Hemmatazad H; Hauser T; Michel BA; Gay RE; Matucci-Cerinic M; Gay S; Distler O; Jüngel A
Arthritis Rheum; 2007 Aug; 56(8):2755-64. PubMed ID: 17665426
[TBL] [Abstract][Full Text] [Related]
18. Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation.
Künzel SR; Hoffmann M; Weber S; Künzel K; Kämmerer S; Günscht M; Klapproth E; Rausch JSE; Sadek MS; Kolanowski T; Meyer-Roxlau S; Piorkowski C; Tugtekin SM; Rose-John S; Yin X; Mayr M; Kuhlmann JD; Wimberger P; Grützmann K; Herzog N; Küpper JH; O'Reilly M; Kabir SN; Sommerfeld LC; Guan K; Wielockx B; Fabritz L; Nattel S; Ravens U; Dobrev D; Wagner M; El-Armouche A
Circ Res; 2021 Oct; 129(8):804-820. PubMed ID: 34433292
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
20. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
